DK1897558T3 - Fast præparat af 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-on - Google Patents

Fast præparat af 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-on

Info

Publication number
DK1897558T3
DK1897558T3 DK06747305.8T DK06747305T DK1897558T3 DK 1897558 T3 DK1897558 T3 DK 1897558T3 DK 06747305 T DK06747305 T DK 06747305T DK 1897558 T3 DK1897558 T3 DK 1897558T3
Authority
DK
Denmark
Prior art keywords
solid preparation
cellulose
melting point
poorly water
low melting
Prior art date
Application number
DK06747305.8T
Other languages
English (en)
Inventor
H Suzuki
Y Ebisawa
T Yoshinari
Original Assignee
Norgine Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norgine Bv filed Critical Norgine Bv
Application granted granted Critical
Publication of DK1897558T3 publication Critical patent/DK1897558T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06747305.8T 2005-06-09 2006-06-09 Fast præparat af 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-on DK1897558T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005170172 2005-06-09
PCT/JP2006/312078 WO2006132440A1 (ja) 2005-06-09 2006-06-09 固形製剤

Publications (1)

Publication Number Publication Date
DK1897558T3 true DK1897558T3 (da) 2013-12-09

Family

ID=37498616

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06747305.8T DK1897558T3 (da) 2005-06-09 2006-06-09 Fast præparat af 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-on

Country Status (10)

Country Link
US (2) US20090208584A1 (da)
EP (1) EP1897558B1 (da)
JP (1) JP5044398B2 (da)
CA (1) CA2611451C (da)
DK (1) DK1897558T3 (da)
ES (1) ES2434072T3 (da)
PL (1) PL1897558T3 (da)
PT (1) PT1897558E (da)
SI (1) SI1897558T1 (da)
WO (1) WO2006132440A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136393A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
EP2155170A2 (en) * 2007-06-08 2010-02-24 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
JP5352474B2 (ja) * 2007-12-28 2013-11-27 沢井製薬株式会社 口腔内崩壊錠およびその製造方法
MX2011001150A (es) * 2008-07-31 2011-03-29 Takeda Pharmaceutical Composicion farmaceutica solida.
UY32126A (es) * 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
JP2010254623A (ja) 2009-04-24 2010-11-11 Takeda Chem Ind Ltd ベンゾオキサジノン化合物の結晶
CN102548556A (zh) * 2009-07-28 2012-07-04 武田药品工业株式会社 片剂
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
TWI511967B (zh) 2010-06-16 2015-12-11 Takeda Pharmaceutical 醯胺化合物之結晶
AU2012278831A1 (en) * 2011-07-07 2014-01-16 Arqule, Inc Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
KR101591614B1 (ko) * 2011-10-19 2016-02-18 닛뽕소다 가부시키가이샤 요석 방지제
WO2013092786A1 (en) * 2011-12-23 2013-06-27 Norgine B.V. Compositions comprising cetilistat
NL2009995C2 (en) * 2011-12-23 2013-09-18 Norgine Bv Compositions.
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
EP2814466B1 (en) * 2012-02-15 2018-12-26 Takeda Pharmaceutical Company Limited Tablet comprising 1-(4-methoxybutyl)-n-(2-methylpropyl)-n-[(3s,5r)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1h-benzimidazole-2-carboxamide or a salt thereof
DE202012104963U1 (de) 2012-12-19 2013-01-14 Norgine B.V. Cetilistat aufweisende Zusammensetzungen
JP5686452B2 (ja) * 2013-03-01 2015-03-18 塩野義製薬株式会社 イルベサルタンを含有する錠剤
CN104971051A (zh) * 2014-04-11 2015-10-14 刘小斌 一种赛利司他片及制备方法
CN106310287B (zh) * 2015-06-25 2019-03-19 山东省药学科学院 新利司他药用组合物及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB224671A (en) 1923-10-03 1924-11-20 Ismay Annie Fownes Improvements in and relating to wire-netting fencing
JPS5116491B2 (da) 1971-10-08 1976-05-25
US4623588A (en) * 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
JP2842244B2 (ja) * 1993-09-21 1998-12-24 武田薬品工業株式会社 イデベノン粒剤およびその製造法
JP3532999B2 (ja) * 1995-03-24 2004-05-31 株式会社ロッテ 新規なタンニン類およびこれを有効成分とするリパーゼ阻害剤
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
JPH10182436A (ja) * 1996-10-31 1998-07-07 Takeda Chem Ind Ltd 固形医薬製剤
US6172095B1 (en) * 1996-11-25 2001-01-09 The Procter & Gamble Company Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
JP3926888B2 (ja) * 1997-05-27 2007-06-06 株式会社カネカ コレステロール低下剤
WO1999022735A1 (en) 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
TWI257311B (en) * 1998-07-28 2006-07-01 Takeda Chemical Industries Ltd Rapidly disintegrable solid preparation
JP3774118B2 (ja) * 1998-08-14 2006-05-10 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害剤を含む製薬学的組成物
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
AR022204A1 (es) * 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
JP2000273039A (ja) * 1999-01-20 2000-10-03 Taisho Pharmaceut Co Ltd 口腔内崩壊性組成物
WO2000078292A1 (fr) * 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Preparations solides a desintegration rapide
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
ATE271049T1 (de) 1999-11-10 2004-07-15 Takeda Chemical Industries Ltd Fünfgliedrige n-heterocyclen mit hypoglykämischer und hypolipidemischer wirkung
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
JP2001316249A (ja) * 2000-05-11 2001-11-13 Lion Corp 錠剤型医薬組成物
WO2001087834A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
JP2001335469A (ja) * 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
PL204443B1 (pl) * 2000-07-28 2010-01-29 Hoffmann La Roche Kompozycja farmaceutyczna zawierająca inhibitor lipazy, sposób wytwarzania kompozycji farmaceutycznej, zestaw do leczenia otyłości, zastosowanie kompozycji farmaceutycznej oraz zastosowanie orlistatu i substancji wiążącej kwasy żółciowe
US6967212B2 (en) * 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
EP1437351A4 (en) 2001-10-19 2005-06-01 Takeda Pharmaceutical AMINE DERIVATIVE
US20050003001A1 (en) * 2001-11-07 2005-01-06 Hisami Yamaguchi Method for improving dissolution of poorly dispersible medicaments
SI21301A (sl) * 2002-09-11 2004-04-30 LEK farmacevtska družba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
WO2004069834A1 (ja) * 2003-02-07 2004-08-19 Takeda Pharmaceutical Company Limited 三環性化合物、その製造方法および用途
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
JP2005170172A (ja) 2003-12-10 2005-06-30 Ogura Clutch Co Ltd 車両室内用遮蔽装置
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations

Also Published As

Publication number Publication date
WO2006132440A1 (ja) 2006-12-14
ES2434072T3 (es) 2013-12-13
EP1897558A4 (en) 2012-09-12
EP1897558A1 (en) 2008-03-12
US20090208584A1 (en) 2009-08-20
CA2611451A1 (en) 2006-12-14
PT1897558E (pt) 2013-11-06
CA2611451C (en) 2014-04-22
SI1897558T1 (sl) 2014-03-31
JP5044398B2 (ja) 2012-10-10
EP1897558B1 (en) 2013-09-04
PL1897558T3 (pl) 2014-01-31
US20140178477A1 (en) 2014-06-26
JPWO2006132440A1 (ja) 2009-01-08

Similar Documents

Publication Publication Date Title
DK1897558T3 (da) Fast præparat af 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-on
WO2006113631A3 (en) Bioenhanced compositions
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
HUP0204136A2 (hu) Eljárások az interleukin-2 tüdőbe juttatására
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
TW200608975A (en) Pharmaceutical compositions
WO2005016261A3 (en) Aripiprazole and haloperidol pamoate salts
ATE451925T1 (de) Medizinische zusammensetzung, verfahren zu ihrer herstellung und verfahren zur stabilisierung einer dihydropyridin-verbindung in einer medizinischen zusammensetzung
WO2007005633A3 (en) Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
CA2620594A1 (en) Pharmaceutical composition having improved disintegratability
EA200300740A1 (ru) Фармацевтические композиции, включающие амлодипина малеат
DK2151241T3 (da) Stabilt fast præparat, omfattende 4,5-epoxymorphinanderivat
WO2010038091A3 (en) Compositions comrrising amlodipine and bisoprolol
MY125099A (en) Comminuted form of (s)-2-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) penyl] propanoic acid
DK1635792T3 (da) Stabile farmaceutiske sammensætninger af 2-aza-bicyklo-3.3.0-oktan-3-carboxylsyrederivater
PL1765342T4 (pl) Kompozycja farmaceutyczna zawierająca besylan amlodypiny i dihydrat lizynoprylu oraz sposób jej wytwarzania
DE60233552D1 (de) Fenofibrattabletten
WO2004022699A3 (en) Liquid stable composition of oxazaphosphorine with mesna
RU2008147216A (ru) Жидкая лекарственная композиция
WO2007031326A3 (de) Retardformulierung von 3-(2-dimethylaminomethyl-cyclohexyl)-phenol
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
HK1055675A1 (en) Method for stabilizing a pharmaceutical preparation
IL182549A (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
RU2019110218A (ru) Новые композиции на основе фуразидина и способы их изготовления
BRPI0519248A2 (pt) formulaÇço oral de liberaÇço imediata de um composto ativo, e, mÉtodo para a preparaÇço de uma formulaÇço